Bank-led research in the healthcare sector is predominantly written for and distributed to, a sophisticated institutional audience. Our research is intended to be accessible, written in a language that is understandable, with an actionable investment thesis, and distributed freely to the investing public.
With a focus on micro / small cap companies, we are inherently covering risky names. We will make aggressive calls. We will not always be right. We will own our successes and our failures.
encodelp
@encodelp
$OCUP continues to trend up post Famy deal. Seems likely this momentum continues given additional news of Nyxol NDA… https://t.co/nG5WhpdfTN
encodelp
@encodelp
$SLNO trading well today https://t.co/aSLBanujXz
encodelp
@encodelp
$SLNO should be fun to watch in 2023. Randomized withdrawal study reads out 1H23. Co seems confident FDA will accep… https://t.co/HF50EpySML
encodelp
@encodelp
$XENE updates XEN1101 MDD top-line guidance to 3Q23
encodelp
@encodelp
$NVCN low-float medtech trading under cash. The timelines for pivotal data for their refractory angina program are… https://t.co/zXZMrNzlFH
We will provide regular updates on companies we follow through our newsletter. We also welcome investors to reach out directly to us at ideas@encodelp.com with any questions or suggestions.